Overview

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Status:
Completed

Trial end date:
2019-12-20

Target enrollment:

Participant gender:

Summary

A phase I/II trial to evaluate the safety and efficacy of nivolumab at the fixed dose 40 mg in patients with relapsed or refractory Hodgkins lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

St. Petersburg State Pavlov Medical University

Treatments:

Antibodies, Monoclonal
Nivolumab